Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part. Once the MTD has been defined, the MTD expansion part will be opened for enrollment.
Critère d'inclusion
- Breast Cancer,colon cancer,Ovarian Cancer,Endometrium Cancer